Developer docs
API playgroundTry for free, no card

Search company profiles

Alumis

Full company profile

uuid00003hj

Namestring
Alumis
Legal namestring
Alumis Inc.
Websiteurl
alumis.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Alumis Inc. is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in South San Francisco, California, developing targeted therapies for immune-mediated diseases. The company is publicly traded on NASDAQ under the ticker ALMS following a January 2026 upsized offering that raised approximately $345.1M, and it operates a portfolio of three core clinical-stage assets: envudeucitinib (ESK-001), a next-generation allosteric oral TYK2 inhibitor designed for maximal 24-hour inhibition of IL-23/IL-17 and type I interferon signaling; A-005, a brain-penetrant allosteric TYK2 inhibitor targeting neuroinflammatory and neurodegenerative diseases; and lonigutamab, a subcutaneous anti-IGF-1R monoclonal antibody for thyroid eye disease acquired through the February 2025 merger with ACELYRIN. Underlying the pipeline is a proprietary data analytics platform that integrates multi-omic and clinical data to identify targets, indications, and patient segments, with the company stating the platform identified approximately 20 diseases impacted by TYK2.

Alumis' lead clinical catalyst is the Phase 3 ONWARD1 and ONWARD2 program in moderate-to-severe plaque psoriasis, where envudeucitinib achieved a 68% PASI 90 response rate and 41% PASI 100 (complete clearance) at Week 24 across 1,771 enrolled patients, outperforming the typical 50–55% benchmark for oral TYK2 inhibitors. The program is positioned for NDA submission in H2 2026, with a parallel Phase 2b LUMUS study in systemic lupus erythematosus toplining in Q3 2026 and a Phase 2 study of A-005 in multiple sclerosis planned for H1 2026. The pipeline also includes undisclosed programs targeting IRF5 and additional targets, all developed using the company's precision-medicine framework.

The business model is pre-commercial: Alumis generates no meaningful product revenue and reported approximately $1.93M in Q4 2025 from licensing/collaboration activities. The company employs 101–250 staff and is building a specialty pharmaceutical commercial organization, including a Chief Commercial Officer hired from Amgen/Horizon Therapeutics in 2025 with experience launching TEPEZZA. Future revenue is expected to come from U.S. specialty pharmacy distribution of envudeucitinib, lonigutamab, and A-005, supplemented by the Kaken Pharmaceutical co-commercialization arrangement in Japan and additional regional licensing deals. As of early 2026 the company held approximately $569.5M in cash against a $93.1M quarterly burn, providing runway into Q4 2027.

Short descriptiontext

Alumis is a clinical-stage biopharmaceutical company developing next-generation oral TYK2 inhibitors and a subcutaneous anti-IGF-1R antibody for immune-mediated diseases including plaque psoriasis, systemic lupus erythematosus, thyroid eye disease, and neuroinflammatory conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tyrosine kinase inhibitors, autoimmune disease therapies, monoclonal antibody therapeutics, immune-mediated disease treatments, precision medicine biopharmaceuticals
Industry1 code
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals / Specialty Therapeutics for Immune-Mediated Diseases
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company expecting to generate revenue through commercial sales of envudeucitinib and other pipeline products upon FDA approval. Revenue will come from prescription drug sales targeting immune-mediated diseases, distributed through specialty pharmacy channels.

investing.com
2Licensing and Strategic Partnerships
TypeLicensing Royalties
Description

Company has retained global rights for all programs except envudeucitinib plaque psoriasis rights shared with Kaken in Japan. This creates potential licensing revenue streams from co-development and co-commercialization arrangements in specific geographic markets.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alumis is a clinical-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases. Its core offerings are three clinical-stage drug candidates: envudeucitinib (an oral allosteric TYK2 inhibitor for plaque psoriasis, SLE, and neuroinflammatory conditions), lonigutamab (a subcutaneous anti-IGF-1R monoclonal antibody for thyroid eye disease), and A-005 (a brain-penetrant allosteric TYK2 inhibitor for multiple sclerosis, Alzheimer's, and Parkinson's). The company is preparing for first commercial launches upon FDA approval and will distribute through specialty pharmacy channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 68% PASI 90 response rate at Week 24 in Phase 3 ONWARD1 trial for plaque psoriasis
+5 more records
Product overview1 text field

Alumis is a clinical-stage biopharmaceutical company advancing a late-stage portfolio of next-generation targeted therapies for immune-mediated diseases. The company's pipeline consists of three core clinical programs: Envudeucitinib (ESK-001), an oral TYK2 inhibitor in Phase 3 for plaque psoriasis and Phase 2b for systemic lupus erythematosus; Lonigutamab, a subcutaneous anti-IGF-1R monoclonal antibody for thyroid eye disease (acquired through merger with Acelyrin); and A-005, a brain-penetrant TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company also maintains undisclosed programs targeting IRF5 and additional targets. Alumis leverages a proprietary data analytics platform to drive precision medicine development.

Product and service3 records
1Envudeucitinib (ESK-001)
CategoryOral TYK2 Inhibitor (Small Molecule)
Description

A next-generation, highly selective oral allosteric TYK2 inhibitor precision-engineered for maximal 24-hour inhibition to correct immune dysregulation in IL-23/IL-17 driven diseases including plaque psoriasis, systemic lupus erythematosus, and neuroinflammatory conditions. Phase 3 in plaque psoriasis and Phase 2 in SLE.

2Lonigutamab
CategoryAnti-IGF-1R Monoclonal Antibody
Description

A next-generation anti-insulin-like growth factor 1 receptor (anti-IGF-1R) humanized IgG1 monoclonal antibody designed for subcutaneous delivery for thyroid eye disease, with novel epitope binding that triggers rapid receptor internalization and degradation. First subcutaneous anti-IGF-1R therapy to demonstrate efficacy in TED comparable to IV-administered treatments.

3A-005
CategoryCNS-Penetrant TYK2 Inhibitor (Small Molecule)
Description

The first allosteric TYK2 inhibitor with demonstrated ability to cross the human blood-brain barrier, designed for neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Enables targeted treatment within the CNS and periphery.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-06
Description

Merger agreement announced February 2025 creating a late-stage clinical biopharma company. All-stock transaction with Alumis owning approximately 55% of the combined entity. Combined pipeline included Alumis' ESK-001 and ACELYRIN's lonigutamab. Pro forma cash position of approximately $737 million. Expected to close Q2 2025.

2Kaken Pharmaceutical
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Co-commercialization partner for envudeucitinib in plaque psoriasis in Japan. Alumis retains global rights for all other territories and indications including SLE and other potential indications.

alumis.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Bristol Myers Squibb
TypeDirect peer
Description

Markets Sotyktu (deucravacitinib), the first and currently only approved oral allosteric TYK2 inhibitor for plaque psoriasis. Directly competes with envudeucitinib in the same indication and class, and also has major psoriasis/autoimmune franchises (Zeposia, Otezla).

TypeBroad incumbent
Description

Markets Skyrizi (risankizumab) and Rinvoq (upadacitinib), which dominate moderate-to-severe plaque psoriasis and other autoimmune indications (psoriatic arthritis, Crohn's, atopic dermatitis). Sets the efficacy and formulary benchmark that envudeucitinib must compete against at launch.

TypeBroad incumbent
Description

Markets Taltz (ixekizumab) in plaque psoriasis and psoriatic arthritis, and Olumiant (baricitinib) in autoimmune indications. A major incumbent in the immunology space with deep commercial infrastructure that any new oral entrant must contend with.

TypeDirect peer
Description

Developing litfilo (abrocitinib/next-gen oral TYK2 candidate) and markets Xeljanz (tofacitinib) and Cibinqo in autoimmune disease. Direct competitor in the oral TYK2 / JAK inhibitor class for psoriasis and broader autoimmune indications.

TypeEmerging player
Description

Specialty dermatology company marketing Zoryve (roflumilast) topical cream and foam for psoriasis, atopic dermatitis and seborrheic dermatitis. An emerging oral/topical dermatology competitor targeting the same moderate plaque psoriasis prescriber base as Alumis.

TypeBroad incumbent
Description

Acquired Horizon Therapeutics in 2023, gaining TEPEZZA — the leading anti-IGF-1R therapy for thyroid eye disease. Directly competes with Alumis's lonigutamab in TED and has deep rare disease commercial infrastructure overlapping with Alumis's planned specialty pharmacy approach.

TypeBroad incumbent
Description

Markets Dupixent (dupilumab), a leading injectable across atopic dermatitis, asthma and other type 2 inflammatory conditions, and previously acquired Principia Biopharma — Alumis's leadership team's prior company. Represents both a major competitor and a potential strategic acquirer.

TypeEmerging player
Description

Specialty immunology company marketing Rystiggo (rozanolixizumab) and Zilbrysq for autoimmune neurology, and Cimzia/Evenity in other immune indications. Comparable mid-to-large specialty pharma model focused on autoimmune disease launches.

TypeEmerging player
Description

Clinical-stage immunology company developing oral TYK2 and other kinase inhibitors for psoriasis and other autoimmune indications. Direct competitor in the oral kinase space and former employer of Alumis's CMO, Dr. Jörn Drappa.

TypeBroad incumbent
Description

Global pharmaceutical company with a major immunology franchise (Entyvio for IBD) and active development in lupus and other autoimmune indications. Claire Langrish (Alumis SVP Immunology) previously held positions at Takeda, and the company represents a relevant partner/competitor for cross-indication autoimmune programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alumis

Biopharmaceuticals / Specialty Therapeutics for Immune-Mediated Diseasesalumis.com

Alumis is a clinical-stage biopharmaceutical company developing next-generation oral TYK2 inhibitors and a subcutaneous anti-IGF-1R antibody for immune-mediated diseases including plaque psoriasis, systemic lupus erythematosus, thyroid eye disease, and neuroinflammatory conditions.

What Alumis does

Alumis Inc. is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in South San Francisco, California, developing targeted therapies for immune-mediated diseases. The company is publicly traded on NASDAQ under the ticker ALMS following a January 2026 upsized offering that raised approximately $345.1M, and it operates a portfolio of three core clinical-stage assets: envudeucitinib (ESK-001), a next-generation allosteric oral TYK2 inhibitor designed for maximal 24-hour inhibition of IL-23/IL-17 and type I interferon signaling; A-005, a brain-penetrant allosteric TYK2 inhibitor targeting neuroinflammatory and neurodegenerative diseases; and lonigutamab, a subcutaneous anti-IGF-1R monoclonal antibody for thyroid eye disease acquired through the February 2025 merger with ACELYRIN. Underlying the pipeline is a proprietary data analytics platform that integrates multi-omic and clinical data to identify targets, indications, and patient segments, with the company stating the platform identified approximately 20 diseases impacted by TYK2.

Alumis' lead clinical catalyst is the Phase 3 ONWARD1 and ONWARD2 program in moderate-to-severe plaque psoriasis, where envudeucitinib achieved a 68% PASI 90 response rate and 41% PASI 100 (complete clearance) at Week 24 across 1,771 enrolled patients, outperforming the typical 50–55% benchmark for oral TYK2 inhibitors. The program is positioned for NDA submission in H2 2026, with a parallel Phase 2b LUMUS study in systemic lupus erythematosus toplining in Q3 2026 and a Phase 2 study of A-005 in multiple sclerosis planned for H1 2026. The pipeline also includes undisclosed programs targeting IRF5 and additional targets, all developed using the company's precision-medicine framework.

The business model is pre-commercial: Alumis generates no meaningful product revenue and reported approximately $1.93M in Q4 2025 from licensing/collaboration activities. The company employs 101–250 staff and is building a specialty pharmaceutical commercial organization, including a Chief Commercial Officer hired from Amgen/Horizon Therapeutics in 2025 with experience launching TEPEZZA. Future revenue is expected to come from U.S. specialty pharmacy distribution of envudeucitinib, lonigutamab, and A-005, supplemented by the Kaken Pharmaceutical co-commercialization arrangement in Japan and additional regional licensing deals. As of early 2026 the company held approximately $569.5M in cash against a $93.1M quarterly burn, providing runway into Q4 2027.

Alumis firmographics

Firmographics
Name
Alumis
Legal name
Alumis Inc.
Website
https://alumis.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
101–250 employees
Short description
Alumis is a clinical-stage biopharmaceutical company developing next-generation oral TYK2 inhibitors and a subcutaneous anti-IGF-1R antibody for immune-mediated diseases including plaque psoriasis, systemic lupus erythematosus, thyroid eye disease, and neuroinflammatory conditions.
Ownership category
akta.pro rank

Alumis industry classification

Industry
Product category
Biopharmaceuticals / Specialty Therapeutics for Immune-Mediated Diseases
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Tyrosine kinase inhibitors
  • Autoimmune disease therapies
  • Monoclonal antibody therapeutics
  • Immune-mediated disease treatments
  • Precision medicine biopharmaceuticals

Where Alumis is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alumis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company expecting to generate revenue through commercial sales of envudeucitinib and other pipeline products upon FDA approval. Revenue will come from prescription drug sales targeting immune-mediated diseases, distributed through specialty pharmacy channels.
  2. Licensing and Strategic Partnerships: Company has retained global rights for all programs except envudeucitinib plaque psoriasis rights shared with Kaken in Japan. This creates potential licensing revenue streams from co-development and co-commercialization arrangements in specific geographic markets.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Alumis product offering

Product offering

Core offering

Alumis is a clinical-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases. Its core offerings are three clinical-stage drug candidates: envudeucitinib (an oral allosteric TYK2 inhibitor for plaque psoriasis, SLE, and neuroinflammatory conditions), lonigutamab (a subcutaneous anti-IGF-1R monoclonal antibody for thyroid eye disease), and A-005 (a brain-penetrant allosteric TYK2 inhibitor for multiple sclerosis, Alzheimer's, and Parkinson's). The company is preparing for first commercial launches upon FDA approval and will distribute through specialty pharmacy channels.

Product overview

Alumis is a clinical-stage biopharmaceutical company advancing a late-stage portfolio of next-generation targeted therapies for immune-mediated diseases. The company's pipeline consists of three core clinical programs: Envudeucitinib (ESK-001), an oral TYK2 inhibitor in Phase 3 for plaque psoriasis and Phase 2b for systemic lupus erythematosus; Lonigutamab, a subcutaneous anti-IGF-1R monoclonal antibody for thyroid eye disease (acquired through merger with Acelyrin); and A-005, a brain-penetrant TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company also maintains undisclosed programs targeting IRF5 and additional targets. Alumis leverages a proprietary data analytics platform to drive precision medicine development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Envudeucitinib (ESK-001) A next-generation, highly selective oral allosteric TYK2 inhibitor precision-engineered for maximal 24-hour inhibition to correct immune dysregulation in IL-23/IL-17 driven diseases including plaque psoriasis, systemic lupus erythematosus, and neuroinflammatory conditions. Phase 3 in plaque psoriasis and Phase 2 in SLE.
  • Lonigutamab A next-generation anti-insulin-like growth factor 1 receptor (anti-IGF-1R) humanized IgG1 monoclonal antibody designed for subcutaneous delivery for thyroid eye disease, with novel epitope binding that triggers rapid receptor internalization and degradation. First subcutaneous anti-IGF-1R therapy to demonstrate efficacy in TED comparable to IV-administered treatments.
  • A-005 The first allosteric TYK2 inhibitor with demonstrated ability to cross the human blood-brain barrier, designed for neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Enables targeted treatment within the CNS and periphery.

Quantifiable outcome

  • 68% PASI 90 response rate at Week 24 in Phase 3 ONWARD1 trial for plaque psoriasis
  • +5 more outcomes

Companies that use Alumis

Customer profile

Segments4 records

Ideal customer profiles2 records

Alumis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Alumis partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and regional.

  • ACELYRINcoreStrategic or Co-development Partner · 6 February 2025Merger agreement announced February 2025 creating a late-stage clinical biopharma company. All-stock transaction with Alumis owning approximately 55% of the combined entity. Combined pipeline included Alumis' ESK-001 and ACELYRIN's lonigutamab. Pro forma cash position of approximately $737 million. Expected to close Q2 2025.
  • Kaken PharmaceuticalregionalChannel Partner/ Reseller/ DistributorCo-commercialization partner for envudeucitinib in plaque psoriasis in Japan. Alumis retains global rights for all other territories and indications including SLE and other potential indications.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Alumis competitors and assessment

Company assessment

Direct peers

  • Bristol Myers Squibb: Markets Sotyktu (deucravacitinib), the first and currently only approved oral allosteric TYK2 inhibitor for plaque psoriasis. Directly competes with envudeucitinib in the same indication and class, and also has major psoriasis/autoimmune franchises (Zeposia, Otezla).
  • Pfizer: Developing litfilo (abrocitinib/next-gen oral TYK2 candidate) and markets Xeljanz (tofacitinib) and Cibinqo in autoimmune disease. Direct competitor in the oral TYK2 / JAK inhibitor class for psoriasis and broader autoimmune indications.

Broad incumbents

  • AbbVie: Markets Skyrizi (risankizumab) and Rinvoq (upadacitinib), which dominate moderate-to-severe plaque psoriasis and other autoimmune indications (psoriatic arthritis, Crohn's, atopic dermatitis). Sets the efficacy and formulary benchmark that envudeucitinib must compete against at launch.
  • Eli Lilly: Markets Taltz (ixekizumab) in plaque psoriasis and psoriatic arthritis, and Olumiant (baricitinib) in autoimmune indications. A major incumbent in the immunology space with deep commercial infrastructure that any new oral entrant must contend with.
  • Amgen: Acquired Horizon Therapeutics in 2023, gaining TEPEZZA — the leading anti-IGF-1R therapy for thyroid eye disease. Directly competes with Alumis's lonigutamab in TED and has deep rare disease commercial infrastructure overlapping with Alumis's planned specialty pharmacy approach.
  • Sanofi: Markets Dupixent (dupilumab), a leading injectable across atopic dermatitis, asthma and other type 2 inflammatory conditions, and previously acquired Principia Biopharma — Alumis's leadership team's prior company. Represents both a major competitor and a potential strategic acquirer.
  • Takeda Pharmaceutical: Global pharmaceutical company with a major immunology franchise (Entyvio for IBD) and active development in lupus and other autoimmune indications. Claire Langrish (Alumis SVP Immunology) previously held positions at Takeda, and the company represents a relevant partner/competitor for cross-indication autoimmune programs.

Emerging players

  • Arcutis Biotherapeutics: Specialty dermatology company marketing Zoryve (roflumilast) topical cream and foam for psoriasis, atopic dermatitis and seborrheic dermatitis. An emerging oral/topical dermatology competitor targeting the same moderate plaque psoriasis prescriber base as Alumis.
  • UCB: Specialty immunology company marketing Rystiggo (rozanolixizumab) and Zilbrysq for autoimmune neurology, and Cimzia/Evenity in other immune indications. Comparable mid-to-large specialty pharma model focused on autoimmune disease launches.
  • Ventyx Biosciences: Clinical-stage immunology company developing oral TYK2 and other kinase inhibitors for psoriasis and other autoimmune indications. Direct competitor in the oral kinase space and former employer of Alumis's CMO, Dr. Jörn Drappa.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Alumis social profiles

Digital presence

Alumis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alumis leadership team

Management profile

Number of profiles

Profiles11 records

Alumis subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Alumis funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alumis M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alumis

What does Alumis do?

Alumis is a clinical-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases. Its core offerings are three clinical-stage drug candidates: envudeucitinib (an oral allosteric TYK2 inhibitor for plaque psoriasis, SLE, and neuroinflammatory conditions), lonigutamab (a subcutaneous anti-IGF-1R monoclonal antibody for thyroid eye disease), and A-005 (a brain-penetrant allosteric TYK2 inhibitor for multiple sclerosis, Alzheimer's, and Parkinson's). The company is preparing for first commercial launches upon FDA approval and will distribute through specialty pharmacy channels.

Is Alumis a public or private company?

Alumis is a public company. It is classified as public and is currently operating.

When was Alumis founded?

Alumis was founded in 2021. It employs 101 to 250 people.

Where is Alumis based?

Alumis is headquartered in South San Francisco, United States, in the North America region.

How does Alumis make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Strategic Partnerships.

Who are Alumis's main competitors?

Direct peers on record are Bristol Myers Squibb and Pfizer. Broad incumbents are AbbVie, Eli Lilly, Amgen, Sanofi and Takeda Pharmaceutical. Emerging players are Arcutis Biotherapeutics, UCB and Ventyx Biosciences.

Does Alumis have an API?

No public API is recorded for Alumis.

What industry is Alumis in?

Alumis's product category is Biopharmaceuticals / Specialty Therapeutics for Immune-Mediated Diseases. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketBeatAlumis Inc. (NASDAQ:ALMS) Stock Short Interest Rises 63.4%Short interest in Alumis rose 63.4% to 10.3 million shares as of September 30th. Analysts have a consensus "Moderate Buy" rating with a $33.27 price target, while insiders sold 111,084 shares in the last quarter. The company reported a loss of $1.11 per share for the quarter, missing estimates.MarketBeatAlumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27Alumis Inc. has a consensus target price of $33.27 with a Moderate Buy rating from analysts. Insiders sold 111,084 shares in the last quarter, and the company reported a Q2 loss of $1.11 per share, missing estimates. Analysts forecast a -2.95 EPS for the current fiscal year.Clinical Trials ArenaAlumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impactAlumis reported positive Phase III data for its TYK2 inhibitor envudeucitinib in psoriasis, showing 80% of patients maintained clear scalp at 48 weeks. The company plans to submit a New Drug Application in the final quarter of 2026, but analysts are lukewarm on its impact due to competition from Icotyde and Sotyktu.Investing.comAlumis presents new psoriasis drug data, plans late 2026 filingAlumis presented Phase 3 data for envudeucitinib in moderate-to-severe plaque psoriasis, showing 54% PASI 100 at Week 48 in ONWARD3. The company plans to file a New Drug Application in the fourth quarter of 2026.American Banking and Market NewsComparing Alumis (NASDAQ:ALMS) & Tango Therapeutics (NASDAQ:TNGX)Tango Therapeutics and Alumis are compared on valuation, profitability, and analyst ratings. Tango has higher revenue and earnings but a lower price-to-earnings ratio, while Alumis shows stronger analyst consensus and higher upside. Alumis's Phase 3 trials for ESK-001 are expected in 2024.Defense WorldTango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial AnalysisA financial comparison of Tango Therapeutics and Alumis evaluates institutional ownership, valuation, earnings, profitability, analyst ratings, and risk. Alumis has a stronger consensus rating and higher upside, while Tango Therapeutics beats on 10 of 15 factors. Analysts favor Alumis, with a consensus target price of $33.27 versus $43.46.Ticker ReportHead-To-Head Contrast: BridgeBio Pharma (NASDAQ:BBIO) versus Alumis (NASDAQ:ALMS)BridgeBio Pharma and Alumis are compared on financial metrics, with BridgeBio having higher revenue and lower valuation. Analysts rate Alumis more favorably, citing a higher consensus price target and potential upside. BridgeBio beats Alumis on 8 of 15 factors.AInvestAlumis Plunges 59%, But a Technical Reversal EmergesAlumis stock fell 58.98% recently, but a September 1 long lower shadow suggests a short-term reversal. Fundamentals are dire, with a -6913.72% net margin and -83.03% revenue growth, so the move is speculative. Traders advised a strict stop-loss and no long-term hold.Seeking AlphaAlumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptAlumis Inc. presented at Morgan Stanley's 24th Annual Global Healthcare Conference on September 14, 2026, with CEO Martin Babler and CMO Jorn Drappa. Babler discussed envu, a TYK2 inhibitor, and its Phase III psoriasis data, noting consistent results and strong inhibition. He also compared the data to competitors Takeda and J&J's ICOTYDE.Ticker ReportContrasting Pyxis Oncology (NASDAQ:PYXS) and Alumis (NASDAQ:ALMS)Alumis and Pyxis Oncology are compared on profitability, risk, ownership, and analyst ratings. Alumis beats Pyxis on 9 of 15 factors, with a consensus target price of $33.27 versus $8.75, implying 262% upside. Alumis is favored by analysts.